MediLink Therapeutics Entered into a Collaboration and License Agreement with BioNTech to Develop Next-Generation Anti-Cancer Antibody-Drug Conjugate
- MediLink will receive $70M up front and is eligible to receive additional development, regulatory, and commercial milestones of ~$1B. The companies collaborated to develop a next-generation ADC against HER3
- BioNTech will get an exclusive right globally to develop, manufacture, and commercialize one of MediLink's ADC assets excl. Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region
- MediLink's ADC candidate showed encouraging efficacy and safety in multiple preclinical tumor models by using MediLink's TMALIN technology, and preliminary clinical data further supports the conceptual validation of this candidate
Ref: PR Newswire | Image: MediLink
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.